Stay updated with breaking news from Biosimilar Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
On September 30, 2021, the European Medicines Agency (EMA) released a report entitled “Tailored Scientific Advice for Biosimilar Development,” describing results from its pilot program...
On September 20, 2021, the FDA issued a revised final guidance for industry entitled “Questions and Answers on Biosimilar Development and the BPCI Act” and a third revision to its draft...
/PRNewswire/ -- The "Biopharmaceutical Contract Manufacturing Market by Type of Product, Scale of Operations, Expression System, Company Size, Biologics and...
for those of you looking to catch-up on biosimilars in 2020 and what these experts are most excited about for the year(s) ahead. As the Editorial Board explores which challenges are ahead for 2021, it’s reassuring to note that sustainability is increasingly entering the U.S. biosimilars conversation. As you’ll note in this installment, there are several particularly passionate calls-to-action for companies to confront misinformation, collaborate with stakeholders, and to refine their commercial business models in the name of greater market efficiency. Though there is a lot to be done, it...
To embed, copy and paste the code into your website or blog: As 2020 comes to a close, Big Molecule Watch once again reviews the top developments in the biologics and biosimilars space for 2020. Please keep an eye out this week for posts identifying the most important regulatory, market, and legal developments impacting biosimilars. We start today with our picks for the most significant U.S. regulatory developments related to biosimilars in 2020: 1.FDA and FTC Announced Collaboration to Support Biosimilars Market In February, the U.S. Food and Drug Administration and the Federal Trade Com...